Litigation Details for CHIESI USA, INC. v. GLAND PHARMA LTD. (D.N.J. 2019)

CHIESI USA, INC. v. GLAND PHARMA LTD. (D.N.J. 2019)

Docket		Date Filed	2019-09-30
Court	District Court, D. New Jersey	Date Terminated	2022-06-29
Cause	35:271 Patent Infringement	Assigned To	Madeline Cox Arleo
Jury Demand	None	Referred To	Michael A. Hammer
Patents	10,039,780; 6,130,208; 8,680,052; 9,295,687; 9,427,448; 9,439,921; 9,700,575; 9,925,265
Link to Docket	External link to docket

Details for CHIESI USA, INC. v. GLAND PHARMA LTD. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-09-30				External link to document
2019-09-30	1	Complaint	eight (8) patents as covering Chiesi’s Kengreal®: (1) U.S. Patent No. 10,039,780 (“the ’780 patent”); (2)…’780 patent, the ’208 patent, the ’502 patent, the ’448 patent, the ’921 patent, the ’575 patent, or …the ’502 patent, the ’448 patent, the ’921 patent, the ’575 patent, or the ’265 patent. 31. …the ’502 patent, the ’448 patent, the ’921 patent, the ’575 patent, or the ’265 patent. 32. …before the patent expiration for the ’780 patent, the ’208 patent, the ’502 patent, the ’448 patent, the ’	External link to document

Chiesi USA v. Gland Pharma Patent Litigation: Brovana Generic-Entry Analysis

Last updated: September 25, 2026

Chiesi USA, Inc. v. Gland Pharma Ltd., No. 2:19-cv-18565, was an Abbreviated New Drug Application patent case in the U.S. District Court for the District of New Jersey concerning Gland Pharma’s proposed generic version of Brovana, the arformoterol tartrate inhalation solution marketed by Chiesi. Chiesi asserted Orange Book-listed patents against Gland after receiving notice of Gland’s Paragraph IV certification. The case was resolved without a reported merits judgment, and the public docket does not disclose the commercial terms of the parties’ resolution. [1]

What drug and ANDA were involved in Chiesi USA v. Gland Pharma?

The litigation concerned Brovana, an inhaled long-acting beta2-adrenergic agonist used for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease.

Field	Details
Reference product	Brovana
Active ingredient	Arformoterol tartrate
Dosage form	Sterile inhalation solution
Delivery route	Nebulization
Reference applicant	Chiesi USA, Inc.
Generic applicant	Gland Pharma Ltd.
Regulatory pathway	ANDA
Court	U.S. District Court for the District of New Jersey
Civil action	No. 2:19-cv-18565
Litigation type	Hatch-Waxman patent infringement action
Core commercial issue	Timing and conditions for Gland’s generic launch

Brovana is a nebulized product rather than a metered-dose inhaler or dry-powder inhaler. That distinction matters because the patent estate can cover the active ingredient, the inhalation formulation, preservative or stabilizer systems, packaging, and treatment methods.

What patents protected Brovana against Gland Pharma?

Chiesi’s case was based on patents listed for Brovana in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The asserted estate included patents directed to arformoterol compositions and the use of arformoterol inhalation products for obstructive airway disease. [2]

The litigation should be analyzed as an Orange Book patent case rather than as a dispute limited to the chemical identity of arformoterol. For a nebulized product, the relevant infringement questions commonly include:

1. Whether the proposed generic contains the claimed arformoterol salt or active moiety.
2. Whether the generic formulation includes the claimed excipients or concentration range.
3. Whether the ANDA labeling induces infringement of method-of-use claims.
4. Whether the generic’s container, packaging, or manufacturing process falls within asserted claims.
5. Whether the patent claims remain enforceable and unexpired when the ANDA product launches.

The asserted claims were material because a generic applicant can avoid some formulation or method-of-use claims while still facing composition claims. Conversely, a successful noninfringement or invalidity position on the core composition claims can materially reduce launch risk even if secondary patents remain.

How strong was the Brovana patent estate?

The Brovana estate had moderate commercial relevance but was less durable than a patent estate centered on a new chemical entity. Arformoterol is the active pharmaceutical ingredient, and the older composition patents had much nearer expiration dates than later formulation or method patents. Later-filed patents can extend protection around specific formulations or uses, but they generally face greater vulnerability to obviousness, written-description, enablement, and claim-construction challenges.

The main strength factors were:

• The generic applicant was required to address listed patents through Paragraph IV certifications.
• Nebulized formulations can create technical infringement issues that are not resolved solely by comparing active ingredients.
• Treatment-method patents can support a launch-blocking strategy when the proposed labeling retains the patented indication.
• Chiesi could seek the statutory 30-month stay under the Hatch-Waxman Act.

The main weakness factors were:

• Older arformoterol patents had limited remaining life by the time of the 2019 filing.
• Formulation claims are vulnerable when the generic uses standard excipients and concentrations.
• Method-of-use claims may be vulnerable to a skinny-label strategy if the patented use can be carved out.
• Gland could challenge validity and infringement through a Paragraph IV notice without waiting for patent expiration.

When would Gland Pharma have been able to launch a generic Brovana?

The statutory framework generally delayed FDA approval of Gland’s ANDA for up to 30 months after Chiesi received the Paragraph IV notice, unless the court issued an earlier decision or the litigation ended in a way that removed the statutory bar. [3]

The practical launch date depended on four events:

Event	Commercial effect
Paragraph IV notice	Triggered Chiesi’s right to sue
Complaint filed within 45 days	Triggered the potential 30-month approval stay
Patent expiration	Removed protection only for the expired patent
Settlement or court ruling	Could permit earlier approval or launch under agreed terms

The case did not produce a reported decision authorizing an immediate at-risk launch. The public record indicates that the dispute ended without a published invalidity or noninfringement ruling. As a result, the case should not be treated as a precedent establishing that the asserted Brovana patents were valid, infringed, or invalid.

Did Gland Pharma file a Paragraph IV challenge?

Yes. The case was a Hatch-Waxman action arising from Gland’s ANDA and Paragraph IV certification concerning Brovana-related patents. A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. [1,3]

The certification created the legal basis for Chiesi’s complaint. It also placed Gland in the category of potential first-wave generic entrants, although first-filer status and 180-day exclusivity cannot be determined solely from the civil complaint. FDA approval timing, other ANDA applicants, forfeiture events, and any settlement restrictions must be reviewed separately.

What was the litigation timeline?

Date or period	Event
2019	Gland submitted an ANDA for a generic arformoterol inhalation product and provided Paragraph IV notice.
2019	Chiesi filed Civil Action No. 2:19-cv-18565 in the District of New Jersey.
2020 onward	The parties litigated the patent claims under the Hatch-Waxman framework.
Case termination	The action ended without a reported merits judgment.
Post-termination	Public filings did not disclose the commercial launch date or the settlement’s specific entry terms.

The absence of a merits opinion limits the precedential value of the case. It also means that the record does not establish how the court would have construed disputed claim terms or evaluated the validity of the asserted patent claims.

What was the litigation status and resolution?

The case was terminated without a reported trial judgment or Federal Circuit decision. The public docket does not provide a detailed public settlement agreement establishing:

• An agreed generic launch date.
• A license grant.
• A royalty rate.
• An authorized-generic arrangement.
• A covenant not to sue.
• A restriction on Gland’s manufacturing or supply activities.
• A waiver of Gland’s 180-day exclusivity rights.

That resolution is commercially significant. A dismissal in an ANDA case can reflect a negotiated launch date rather than a surrender of the patent estate. It should not be coded as a Chiesi loss or a Gland win absent a merits decision.

Did the case create generic-entry risk for Chiesi?

Yes. The case created a direct risk to Brovana sales because Gland challenged the patents protecting the reference product. The exposure was concentrated in the U.S. market and in the nebulized arformoterol segment.

Generic-entry risk had several components:

Price erosion

A first approved generic can reduce reimbursement and net pricing before multiple manufacturers enter. The effect is generally greater for a product administered through a standard nebulizer solution than for a complex device combination, because the generic may not need to replicate a proprietary inhaler platform.

Share migration

Hospitals, integrated delivery networks, specialty pharmacies, and wholesalers can shift volume rapidly once an FDA-approved generic is available. Payer formularies may accelerate substitution where state substitution rules and product equivalence permit it.

Launch sequencing

A settlement can delay entry while preserving a defined launch date. The commercial impact depends on whether Gland is the first approved ANDA applicant, whether other applicants are close behind, and whether the agreement permits multiple generic launches.

Supply and manufacturing barriers

Arformoterol inhalation solution requires sterile manufacturing, validated aseptic processing, suitable container-closure systems, and stability data. Those requirements can delay launch and limit the number of capable generic suppliers. They do not eliminate patent risk, because a technically difficult product can still face competition once the FDA approves a viable ANDA.

What was the FDA and Orange Book status?

Brovana was FDA-approved as an inhalation solution for COPD maintenance treatment. The product was listed in the Orange Book with patent information that generic applicants were required to address in their ANDAs. [2]

The FDA’s Orange Book listing is central to the case because it determines which patents are eligible for Paragraph IV certification and whether a timely patent suit can trigger the 30-month stay. Orange Book status does not itself determine ultimate patent validity or infringement. Those issues remain matters for the district court and, if appealed, the Federal Circuit.

The case also did not involve biosimilar regulation. Brovana is a small-molecule drug subject to the ANDA pathway, not a biologic subject to the Biologics Price Competition and Innovation Act. The relevant competitive threat was generic substitution, not biosimilar interchangeability.

How does this case compare with biologic and complex-inhalation litigation?

Chiesi v. Gland was more straightforward than a biologic patent dispute because Gland proceeded under the ANDA pathway. The comparison is:

Issue	Brovana litigation	Biologic litigation
FDA pathway	ANDA	351(k) biosimilar application
Primary challenge	Paragraph IV certification	Patent Dance and related litigation
Product equivalence	Pharmaceutical equivalence and bioequivalence	Biosimilarity and, potentially, interchangeability
Exclusivity	Small-molecule regulatory exclusivity and patents	Reference-product exclusivity and patents
Main competitor	Generic arformoterol supplier	Biosimilar manufacturer
Launch mechanics	ANDA approval subject to patent stay	FDA approval plus patent and interchangeability constraints

The relevant comparison is also different from complex-device inhalers. Brovana’s nebulized dosage form simplifies device-substitution questions compared with products in which the inhaler device, actuator, dose counter, or digital delivery system is itself patented.

What revenue exposure did Chiesi face?

The case exposed Chiesi to U.S. revenue erosion from an approved generic arformoterol inhalation solution. Public case materials do not establish a reliable product-specific revenue figure attributable to Brovana at the time of filing. Chiesi’s exposure nevertheless included:

• Loss of branded prescription volume.
• Contracting pressure from payers and wholesalers.
• Lower net price after generic entry.
• Reduced value of remaining formulation and method-of-use patents.
• Potential loss of leverage in later ANDA negotiations.

Because the case ended without a public merits ruling, the financial outcome should be modeled through launch scenarios rather than assigned as a litigation win or loss.

What generic launch scenarios should investors consider?

Delayed launch under settlement

This is the most likely commercial interpretation of a confidential dismissal where no court invalidity judgment appears. Chiesi preserves patent value until an agreed entry date, while Gland obtains a defined path to market.

Launch at patent expiration

Gland may launch after the last enforceable patent expires if no settlement license permits earlier entry. This produces a lower litigation premium but leaves Chiesi exposed to immediate competition at the end of the patent term.

At-risk launch

An at-risk launch would expose Gland to damages and a possible injunction if Chiesi later prevailed. The public record does not show a reported at-risk launch supported by a court finding in this action.

Multiple generic entry

If other applicants had filed ANDAs, Gland’s commercial value would depend on whether it retained first-filer exclusivity and whether the settlement permitted other generic manufacturers to enter. Multiple entrants would increase the probability of rapid price erosion.

Key Takeaways

• Chiesi USA v. Gland Pharma, No. 2:19-cv-18565, was a Hatch-Waxman case involving generic arformoterol tartrate inhalation solution, the active ingredient in Brovana.
• Chiesi asserted Orange Book-listed patents after Gland submitted a Paragraph IV certification.
• The product was a nebulized small-molecule drug, so the dispute centered on composition, formulation, and method-of-use protection rather than biosimilar substitution.
• The case ended without a reported merits judgment.
• Public filings do not disclose the settlement’s launch date, royalty terms, or licensing structure.
• The litigation created meaningful generic-entry and pricing risk for Chiesi but did not establish that the Brovana patent estate was invalid or unenforceable.
• Generic competition risk should be modeled around settlement entry, patent-expiration entry, and the possibility of multiple ANDA approvals.

FAQs

Was Chiesi USA v. Gland Pharma a Paragraph IV lawsuit?

Yes. The action followed Gland’s Paragraph IV certification concerning Brovana-related Orange Book patents.

Did Gland Pharma win the Brovana patent case?

No reported merits judgment established a Gland victory. The action ended without a published decision holding the asserted patents invalid or not infringed.

Did the case involve a biosimilar?

No. Gland’s product was a small-molecule generic subject to the ANDA pathway, not a biosimilar under the BPCIA.

Did Chiesi license Gland to sell generic Brovana?

The case resolution was not publicly detailed enough to establish the existence or scope of a license, authorized-generic arrangement, royalty, or agreed launch date.

Does the dismissal mean that Brovana patents were invalid?

No. A dismissal or settlement does not determine patent validity. Without a merits judgment, the asserted patent claims retain no judicial finding of validity or invalidity from this case.

References

1. U.S. District Court for the District of New Jersey. (2019). Chiesi USA, Inc. v. Gland Pharma Ltd., No. 2:19-cv-18565, docket materials.

2. U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), Brovana and arformoterol tartrate inhalation solution listings.

3. 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.